Cancer drug: Natco Pharma told to file reply by Aug 25
August 21st, 2012 - 9:05 pm ICT by IANSChennai, Aug 21 (IANS) The Intellectual Property Appellate Board (IPAB) Tuesday asked the Hyderabad-based Natco Pharma to reply by Aug 25 on Bayer Corp’s plea against the issuance of licence to it to sell the generic equivalent of Bayer’s cancer drug Nexavar.
The board adjourned the hearing to the first week of the next month while declining to impose any costs on Natco Pharma for not filing its reply till date. It also refused to order a stay on the latter’s licence to make and sell generic cancer drug sorafenib tosylate.
Bayer Corp, the north American subsidiary of German company Bayer AG, filed the petition challenging the March order of the Controller General of Patents, Designs and Trade Marks of compulsorily licensing Natco Pharma to market the generic version of Nexavar.
Bayer filed the petition against Natco Pharma, the controller of general patents and the central government.
Incidentally, this was the first time that the compulsory licence provision in the Indian Patent Act was invoked in India.
Bayer’s drug costs around Rs.280,000 for a month’s course whereas Natco Pharma sells the same for around Rs.8,000 for a month’s course.
Arguing for Bayer, senior counsel Sudhir Chandra said the licence given to Natco Pharma had international ramifications and had caused severe injury to his client.
He said another pharma company, Cipla, was also selling the same drug at around Rs.5,000 for a month’s course.
Later speaking to reporters, Chandra said: “The court has taken note of the fact that injury is caused to Bayer. They will not grant any more time to Natco to file its reply. Natco has to file its reply by Aug 25.”
Speaking to IANS by phone from New Delhi, Natco Pharma’s counsel Rajeshwari Hariharan said the replies will be filed by Aug 25.
She said many countries like Canada, Brazil, Thailand and others had similar compulsory licensing provisions and India was not an exception.
- Public not to be hit if Natco Pharma licence cancelled: Bayer - Sep 03, 2012
- Stay on cancer drug licence may harm public: Natco Pharma - Sep 05, 2012
- US pushing India to hike cancer drug price - Jul 13, 2012
- Why don't you reduce cancer drug price, SC asks Novartis - Sep 11, 2012
- Patents law provisions conflicting, Novartis tells SC - Sep 18, 2012
- Piramal, Baxter settle patent issue - Nov 01, 2011
- Gilead's model to enhance availability of anti-AIDS drug - Feb 22, 2009
- Ranbaxy to launch anti-diabetic drug Actos by 2012 - Mar 15, 2010
- Ranbaxy ordered to improve India, US plants - Jan 26, 2012
- MNCs gaining control on Indian drug market - Aug 04, 2010
- Victory for access to medicines as Valaganciclovir patent is overturned - May 07, 2010
- Ranbaxy approved to make first generic version of Lipitor - Dec 01, 2011
- SC again asks Novartis to cut cancer drug price - Sep 12, 2012
- Ranbaxy posts $210 mn net profit - May 11, 2010
- Trade pact with EU won't impact pharma industry: India - Dec 10, 2010
Tags: american subsidiary, bayer ag, bayer corp, cancer drug, compulsory licensing, controller general, generic equivalent, hariharan, indian patent act, international ramifications, ipab, natco pharma, nexavar, nexavar bayer, patents designs, pharma company, rajeshwari, rs 8, sorafenib, tosylate